December 5, 2019

FOCUS ON DME/DR

Tracking anti-VEGF use among Medicare Part B beneficiaries Anti-VEGF agents have ushered in a new era of treatment for retinal and choroidal neovascularization. Here’s what researchers have learned in determining how these agents have evolved over time, specifically regarding trends for U.S. Medicare Part B beneficiaries. Learn more ADVERTISEMENT

Myopia may prove beneficial in preventing DR development New research has shown that a longer axial length may prove protective of incident diabetic retinopathy. Find out